Pressbee - Medscape :
Watch the post from Tofersen Linked to Slow but Positive ALS Outcomes, Now to the details :
An open-label extension of the phase 3 VALOR trial shows statistically significant benefits for the novel antisense oligonucleotide tofersen in patients with amyotrophic lateral sclerosis.
Medscape Medical News
For more, read the news from the source
Tofersen Linked to Slow but Positive ALS Outcomes
This was the summery for Tofersen Linked to Slow but Positive ALS Outcomes We hope that we have succeeded by sharing the full details of this topic.
Medscape Tofersen Linked to Slow but Positive ALS Outcomes An open-label extension of the phase 3 VALOR trial shows statistically significant benefits for the novel antisense oligonucleotide tofersen in patients with amyotrophic lateral sclerosis.Medscape Medical News
Please note that the original topic has been published and is available on Medscape the editing team at PressBee have verified it and it may have been partially modified or quoted from it. You can read and follow this news or topic from its main source.
